Antiviral activity of retrocyclin RC-101, a Candidate microbicide against cell-associated HIV-1

AIDS Research and Human Retroviruses

Volumn 29, Issue 2, 2013, Pages 391-396

  Gupta, Phalguni ^a   Lackman Smith, Carol ^b   Snyder, Beth ^b   Ratner, Deena ^a   Rohan, Lisa C ^c   Patton, Dorothy ^d   Ramratnam, Bharat ^e   Cole, Alexander M ^f  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e BROWN UNIVERSITY   (United States)

^f UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; MICROBICIDE; POLYPEPTIDE ANTIBIOTIC AGENT; RETROCYCLIN RC 101; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CELL COMMUNICATION; CLADISTICS; CYTOTOXICITY; DISEASE TRANSMISSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PH; PRIORITY JOURNAL; SEMINAL PLASMA;

ANTIVIRAL AGENTS; CELLS, CULTURED; DEFENSINS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; PEPTIDES;

EID: 84872965125     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0135     Document Type: Article

References (31)

1. Carballo-Dieguez A, Stein Z, Saez H, et al.: Frequent use of lubricants for anal sex among men who have sex with men: The HIV prevention potential of a microbicidal gel. Am J Public Health 2000;90:1117-1121. (Pubitemid 30445367)
2. Darroch JE and Frost JJ: Women's interest in vaginal microbicides. Fam Plann Perspect 1999;31:16-23. (Pubitemid 29072111)
3. Gross M, Holte SE, Marmor M, et al.; HIVNET Vaccine Preparedness Study 2 Protocol Team. Anal sex among HIV-seronegative women at high risk of HIV exposure. J Acquir Immune Defic Syndr 2000;24:393-398.
4. Fiscus SA, Pilcher CD, Miller WC, et al.: Rapid, real-time detection of acute HIV infection in patients in Africa. J Infect Dis 2007;195:416-424. (Pubitemid 46146120)
5. Gupta P, Mellors J, Kingsley L, et al.: High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors. J Virol 1997;71:6271-6275. (Pubitemid 27304979)
6. Vernazza PL, Eron JJ, Cohen MS, et al.: Detection and biologic characterization of infectious HIV-1 in semen of seropositive men. AIDS 1994;8:1325-1329. (Pubitemid 24267758)
7. Vernazza PL, Eron JJ, and Fiscus SA: Sensitive method for the detection of infectious HIV in semen of seropositive individuals. J Virol Methods 1996;56:33-40. (Pubitemid 26078411)
8. Gupta P, Collins KB, Ratner D, et al.: Memory CD4+ T cells are the earliest detectable human immunodeficiency virus type 1 (HIV-1)-infected cells in the female genital mucosal tissue during HIV-1 transmission in an organ culture system. J Virol 2002;76:9868-9876. (Pubitemid 35006526)
9. Garcia-Lerma JG, Otten RA, Qari SH, et al.: Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 2008;5:e28.
10. Jespers VA, Van Roey JM, Beets GI, et al.: Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers. J Acquir Immune Defic Syndr 2007;44:154-158. (Pubitemid 46292217)
11. Rosen RK, Morrow KM, Carballo-Dieguez A, et al.: Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: A mixed-methods study. J Womens Health (Larchmt) 2008;17:383-392. (Pubitemid 351457833)
12. Woolfson AD, Malcolm RK, Morrow RJ, et al.: Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int J Pharm 2006;325:82-89. (Pubitemid 44573697)
13. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al.: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329:1168-1174 [erratum in Science 2011; 333:524].
14. Ketas TJ, Schader SM, Zurita J, et al.: Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes. Virology 2007;364:431-440. (Pubitemid 46873705)
15. Veazey RS, Klasse PJ, Schader SM, et al.: Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virusYcell fusion. Nature 2005;438:99-102. (Pubitemid 41599827)
16. Lackman-Smith C, Osterling C, Luckenbaugh K, et al.: Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides. Antimicrob Agents Chemother 2008;52:1768-1781. (Pubitemid 351614671)
17. Cole AM, Hong T, Boo LM, et al.: Retrocyclin: A primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proc Natl Acad Sci USA 2002;99:1813-1818. (Pubitemid 34168972)
18. Munk C, Wei G, Yang OO, et al.: The h-defensin, retrocyclin, inhibits HIV-1 entry. AIDS Res Hum Retroviruses 2003;19: 875-881. (Pubitemid 37338913)
19. Owen SM, Rudolph DL, Wang W, et al.: RC-101, a retrocyclin-1 analogue with enhanced activity against primary HIV type 1 isolates. AIDS Res Hum Retroviruses 2004;20: 1157-1165. (Pubitemid 39557866)
20. Cole AM, Patton DL, Rohan LC, et al.: The formulated microbicide RC-101 was safe and antivirally active following intravaginal application in pigtailed macaques. PLoS One 2010;5:e15111.
21. Cole AL, Yang OO, Warren AD, et al.: HIV-1 adapts to a retrocyclin with cationic amino acid substitutions that reduce fusion efficiency of gp41. J Immunol 2006;176:6900-6905. (Pubitemid 43787871)
22. Cloyd MW and Moore BE: Spectrum of biological properties of human immunodeficiency virus (HIV-1) isolates. Virology 1990;174:103-116. (Pubitemid 20030956)
23. Buckheit RW Jr and Swanstrom R: Characterization of an HIV-1 isolate displaying an apparent absence of virionassociated reverse transcriptase activity. AIDS Res Hum Retroviruses 1991;7:295-302.
24. Sassi AB, Cost MR, Cole AL, et al.: Formulation development of retrocyclin 1 analog RC-101 as an anti-HIV vaginal microbicide product. Antimicrob Agents Chemother 2011;55: 2282-2289.
25. Gruszecka-Kowalik E, Haugwitz RD, and Zalkow LH: Quinobene, a new potent anti-HIV agent. Biochem Biophys Res Commun 1992;187:1409-1417.
26. Halliday SM, Lackman-Smith C, Bader JP, et al.: Inhibition of human immunodeficiency virus replication by the sulfonated stilbene dye resobene. Antiviral Res 1996;33:41-53. (Pubitemid 26398137)
27. Phillips DM, Tan X, Pearce-Pratt R, et al.: An assay for HIV infection of cultured human cervix-derived cells. J Virol Methods 1995;52:1-13.
28. Okamoto M, Byrn R, Eyre RC, et al.: Seminal plasma induces programmed cell death in cultured peripheral blood mononuclear cells. AIDS Res Hum Retroviruses 2002;18:797-803.
29. Shattock RJ and Moore JP: Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol 2003;1:25-34.
30. Owen DH and Katz DF: A review of the physical and chemical properties of human semen and the formulation of a semen simulant. J Androl 2005;26:459-469. (Pubitemid 40847857)
31. Munch J, Rucker E, Standker L, et al.: Semen-derived amyloid fibrils drastically enhance HIV infection. Cell 2007;131: 1059-1071. (Pubitemid 350235017)